Gliucofaj coated tablets 500 mg. №30

Description

Gliucofaj 500 mg. №30 COMPOSITION
active substance: metformin hydrochloride

1 coated tablet 500 mg contains 500 mg of metformin hydrochloride, which corresponds to 390 mg of metformin

Gliucofaj 500 mg. №30 DOSAGE FORM
Film-coated tablets.

MAIN PHYSICAL AND CHEMICAL PROPERTIES
film-coated tablets 500 mg, 850 mg round tablets with a biconvex surface, white, film-coated

PHARMACOLOGICAL GROUP
Oral hypoglycemic agents, excluding insulins. Biguanides. ATX code А10В А02.

PHARMACOLOGICAL PROPERTIES

Pharmacological

Metformin is a biguanide with an antihyperglycemic effect. Reduces plasma glucose levels both on an empty stomach and after meals. Does not stimulate insulin secretion and does not induce a hypoglycemic effect mediated by this mechanism.

Metformin works in three ways:

leads to a decrease in the production of glucose in the liver by inhibiting gluconeogenesis and glycogenolysis
improves insulin sensitivity in muscles, resulting in improved peripheral glucose uptake and utilization
delays the absorption of glucose in the intestine.
Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthetases. Increases the transport capacity of all known types of membrane glucose transporters (GLUT).

Pharmacokinetics.

Suction. After taking metformin, the time to reach the maximum concentration (T max) is about 2.5 hours. The bioavailability of 500 mg or 800 mg tablets is approximately 50-60% in healthy volunteers. After ingestion, the fraction that is not absorbed and is excreted in the feces is 20-30%.

After oral administration, absorption of metformin is saturable and incomplete.

It is assumed that the pharmacokinetics of metformin absorption is non-linear. When used in the recommended doses of metformin and dosage regimens, stable plasma concentrations are achieved within 24-48 hours and are less than 1 μg / ml. In controlled clinical trials, the maximum levels of metformin in blood plasma (C max) did not exceed 5 μg / ml even at the maximum doses.

INDICATIONS
Type 2 diabetes mellitus with ineffective diet therapy and exercise regimen, especially in overweight patients

as monotherapy or combination therapy in conjunction with other oral hypoglycemic agents or in conjunction with insulin for the treatment of adults.
as monotherapy or combination therapy with insulin for the treatment of children aged 10 years and older and adolescents.
To reduce complications of diabetes in adult patients with type 2 diabetes mellitus and overweight as a first-line drug with ineffective diet therapy.

CONTRAINDICATIONS
Hypersensitivity to metformin or to any other component of the drug
diabetic ketoacidosis, diabetic coma
acute conditions occurring with the risk of developing impaired renal function, such as: dehydration, severe infectious diseases, shock
diseases that can lead to the development of tissue hypoxia (especially acute diseases or exacerbations of a chronic disease) decompensated heart failure, respiratory failure, recent myocardial infarction, shock
hepatic week residual, acute alcohol poisoning, alcoholism.